List of Small Molecule Pharmaceuticals Companies in New Zealand - 2

Healthy Animals. Let's Make It Happen, Together. At Argenta we've been dedicated to animal health from day one. Since 2006, we've been a trusted partner to clients who need our expertise, partnership and no-challenge-too-tough attitude to bringing innovative new animal health products to market. Because we are the only global CRO and CDMO specializing in animal health, we are uniquely able to offer clients of all sizes a comprehensive product development solution from Molecule to Market, at any scale. The day-to-day ethos that drives our company forward is a mission focused on global partnerships, a Molecule to Market approach, and of course, innovation. At the core of our business and our organisation is collaboration — among our global team and with our customers. Working together, we continually challenge ourselves and each other to continue to innovate to develop the best animal health technologies and products possible. From animal scientists to veterinarians to engineers and other industry experts, our 650+ strong global team is a passionate and diverse group united in their commitment to healthy animals. We operate from Research & Development locations and (EMA and FDA) GMP-approved Manufacturing sites in New Zealand, the US, the UK, Spain, and Germany. Our company was founded in New Zealand by Doug Cleverly, a scientist who naturally felt more at home in the lab solving problems than in the boardroom. Doug imbued the company with the spirit of Kiwi ingenuity and a global perspective. He saw a need in the market for an animal health company that could provide the highest quality services to customers of all sizes worldwide. To this day, we are still dedicated to animal health and our founder's legacy of problem-solving and inventiveness lives on within the organisation. Let's get in touch!

Kimer Med is a New Zealand biotech company, developing a pipeline of novel, broad-spectrum antiviral drug candidates. With success against 21 different viruses so far, we're taking on the global health challenge of viral disease and future pandemic threats. Our vision is to end the immense suffering caused by viral disease. There are currently around 220 viruses that cause disease in humans, and only 12 of them have an approved antiviral treatment available. In other words, 95% of viral diseases lack any approved treatment, resulting in enormous unmet medical needs worldwide. We have built and optimised a proprietary platform for the rapid development of broad-spectrum antiviral drug candidates to address these massive medical needs. Our goal is to bring to market a family of broad-spectrum antivirals to treat multiple diseases, and provide pandemic protection. To date we have achieved efficacy against 21 different viruses, and proved the broad-spectrum capabilities of our platform. We are currently in the lead-optimisation phase and nearing phase 1 clinical trials. In 2024, Kimer Med was recognised as one of the Fierce Biotech's 'Fierce 15 of 2024' - the best and brightest of biotech. We were also the recipients of a Merck Emerging Biotech Grant.